PTEN is a tumor suppressor gene mutated in various advanced human neoplasias, including glioblastomas and prostate, breast, endometrial, and kidney cancers. This tumor suppressor is a lipid phosphatase that negatively regulates cell survival and proliferation mediated by phosphatidylinositol 3-kinase͞protein kinase B signaling. Using the Cre-loxP system, we selectively inactivated Pten in murine tissues in which the MMTV-LTR promoter is active, resulting in hyperproliferation and neoplastic changes in Pten-null skin and prostate. These phenotypes had early onset and were completely penetrant. Abnormalities in Pten mutant skin consisted of mild epidermal hyperplasia, whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia (HGPIN) that frequently progressed to focally invasive cancer. These data demonstrate that Pten is an important physiological regulator of growth in the skin and prostate. Further, the early onset of HGPIN in Pten mutant males is unique to this animal model and implicates PTEN mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates in human prostate tumors, these data indicate that PTEN is a critical tumor suppressor in this organ.
PTEN is a tumor suppressor gene mutated in various advanced human neoplasias, including glioblastomas and prostate, breast, endometrial, and kidney cancers. This tumor suppressor is a lipid phosphatase that negatively regulates cell survival and proliferation mediated by phosphatidylinositol 3-kinase͞protein kinase B signaling. Using the Cre-loxP system, we selectively inactivated Pten in murine tissues in which the MMTV-LTR promoter is active, resulting in hyperproliferation and neoplastic changes in Pten-null skin and prostate. These phenotypes had early onset and were completely penetrant. Abnormalities in Pten mutant skin consisted of mild epidermal hyperplasia, whereas prostates from these mice exhibited high-grade prostatic intraepithelial neoplasia (HGPIN) that frequently progressed to focally invasive cancer. These data demonstrate that Pten is an important physiological regulator of growth in the skin and prostate. Further, the early onset of HGPIN in Pten mutant males is unique to this animal model and implicates PTEN mutations in the initiation of prostate cancer. Consistent with high PTEN mutation rates in human prostate tumors, these data indicate that PTEN is a critical tumor suppressor in this organ. P rostate cancer is the most common cancer among North American and European men, affecting 1 in 9 men over 65 years of age (1, 2) . Malignancy of the prostate is the secondleading cause of male cancer deaths and there is currently no effective cure for advanced stages of this disease (1, 2) .
One of the most frequent genetic alterations in prostate tumors occurs at chromosomal region 10q (1, 3) . PTEN is a tumor-suppressor gene residing within 10q23 that is frequently deleted in various advanced human cancers, including glioblastomas and prostate, breast, and endometrial tumors (4, 5) . PTEN mutations have been identified in 10-15% of all prostate tumors and in up to 60% of advanced prostate cancers and cell lines (1, 3, 5, 6) .
Germ-line mutations of PTEN have also been shown to cause Cowden's disease (CD), an autosomal dominant multiple hamartoma syndrome believed to occur at an incidence of at least 1͞200,000 (7) . Hamartomas are benign tumors that develop in multiple organs of CD patients such as the skin and breast. Consistent with PTENЈs role as a tumor suppressor, individuals with CD have an increased susceptibility to developing malignancies of the breast, endometrium, and thyroid (7) .
PTEN is a lipid phosphatase that dephosphorylates phosphoinositides at the 3 position of the inositol ring (8, 9) . The membrane phosphoinositide and second messenger phosphatidylinositol 3,4,5-trisphosphate [PI(3,4,5)P 3 ] has been identified as a physiological substrate of PTEN. Growth factor-stimulated production of PI(3,4,5)P 3 results in activation of cell survival and proliferation mediated by phosphatidylinositol 3-kinase͞protein kinase B (PI3K-PKB͞Akt) signaling. PTEN suppresses tumor growth by negatively regulating this signal transduction pathway (4) . Elevated PKB͞Akt activity and PI(3,4,5)P 3 levels in Ptennull murine cells are associated with a decreased sensitivity to various apoptotic stimuli and accelerated G 1 ͞S progression (9, 10) .
Targeted disruption of murine Pten results in hyperproliferation and embryonic lethality by day 9.5 (4, 9, 11). Young Pten heterozygous mice are highly susceptible to thymic lymphomas, whereas carcinomas of the endometrium, breast, and prostate predominate late in life (12) . Tumors from Pten ϩ/Ϫ mice have lost the wild-type Pten allele, implying that tumor formation requires loss of both Pten alleles. Analysis of tissue-specific Pten-knockout mice has demonstrated that deletion of both Pten alleles results in tumorigenesis of germ cells, T lymphocytes, and mammary epithelium (13) (14) (15) .
To specifically investigate the role of Pten in homeostasis of the prostate and skin epithelium, we used the Cre-loxP system to generate mice with tissue-specific deletion of Pten in these tissues. Data in this study demonstrate an important physiological role for Pten as a negative regulator of growth in the skin and a critical tumor suppressor in the prostate. cells per 3.5-cm dish were trypsinized, and viable cells were counted twice for each sample by using the trypan blue exclusion assay. For crystal violet staining, a 0.05% staining solution was applied to cells for 1 min, and the cells were rinsed and dried for analysis. All keratinocyte experiments were done at least in duplicate and repeated at least three times from newly derived keratinocytes.
Western Blot Analysis. Preparation of whole cell protein lysates, protein resolution by SDS͞8% PAGE and immunoblotting were performed as in ref. 9 . Pten (Cascade, Winchester, MA) and ␤-tubulin (Santa Cruz Biotechnology) antibodies were used at 1:1,000. (17) . Cre-mediated recombination in the prostate of the MMTV-cre mice has recently been documented and is consistent with the ability of hormones to up-regulate the MMTV-LTR promoter (18, 19) .
Results

Deletion of Pten in the Skin
Southern blot analysis using genomic DNA from tissues and cells derived from Pten loxP/loxP ; MMTV-cre mice demonstrate that Cre-mediated recombination occurred in the majority of cells in the thymus and epidermis (Fig. 1A) . Pten was strongly expressed in keratinocytes derived from skin of Pten wt/loxP ; MMTV-cre control animals, but absent in the majority of Pten loxP/loxP ; MMTV-cre keratinocytes (Fig. 1B) . Consistent with Pten's ability to negatively regulate PKB͞Akt activation, levels of activated and phosphorylated PKB͞Akt were increased in Pten mutant keratinocytes (Fig. 1B) . Cre-mediated recombination in the prostate of Pten mutant males was investigated by PCR of the Pten-loxP locus. Amplification of an 849-bp PCR product specific for Pten deletion was detected in prostate tissue from Pten loxP/loxP ; MMTV-cre and Pten wt/loxP ; MMTV-cre mice (Fig. 1C) . Together, these data indicate that Cre-mediated recombination of the Pten allele occurred in the epidermis, prostate, and thymus of Pten loxP/loxP ; MMTV-cre mice.
Deletion of Pten was also detected in mammary tissue from Pten loxP/loxP ; MMTV-cre mice (data not shown). A severe developmental defect was observed in mammary epithelium from these females and will be described elsewhere. ; MMTV-cre mutant mice were viable and newborns appeared normal and healthy. However, by 7 days of age, skin on the ventral surface of Pten loxP/loxP ; MMTV-cre animals appeared thickened and wrinkled compared with heterozygous Pten wt/loxP ; MMTV-cre controls ( Fig. 2A) . By P21, the coat of Pten loxP/loxP ; MMTV-cre mice was shaggy and ruffled compared with the smooth coat on control mice (Fig. 2B) . Appendages of Pten mutant mice such as ears and eyelids were thicker than those of control mice (data not shown).
Abnormalities in Pten mutant skin were further investigated by sectioning and histological staining. Epidermis from Pten mutant animals was acanthotic (hyperplastic) by P7 and appeared papillary by P21 (Fig. 2 D and F) . Epidermis of Pten mutant skin was Ͼ2-fold thicker than controls by 6 wk (Fig. 2M) . Hyperplastic changes in the Pten-null epidermis included hyperkeratosis and hypergranulosis ( Fig. 2F and Fig. 5 , which is published as supporting information). Sebaceous glands were more abundant in the dermis of Pten mutant compared with control skin (Fig. 2D ). Whereas cells occasionally appeared hypertrophied in the Pten mutant epidermis (Fig. 2F and Fig. 5  D and F) , cultured keratinocytes lacking Pten were only mildly enlarged (Ͻ10%, data not shown).
Acanthosis with hyperkeratosis and hypergranulosis were observed on the palmoplantar regions of paws from Pten mutant mice that were similar to the benign tumors on the hands and feet of patients with CD ( Fig. 2H) (20, 21) . Whereas no benign tumors were observed in hair follicles or tongue of Pten mutant mice, these tissues were mildly hyperplastic in the absence of Pten ( Fig. 2 J and L) . Thus, loss of Pten leads to development of palmoplantar hamartomas and hyperplasia of the hair follicle and tongue epithelium in mice.
A failure of keratinocytes to undergo terminal differentiation could result in excessive cell divisions and epidermal hyperplasia. The differentiation program of keratinocytes lacking Pten was intact in vivo ( Fig. 5 ) and in vitro (data not shown). However, keratinocytes in the proliferative and differentiated cell layers of Pten mutant epidermis were each increased in number by Ͼ50% compared with controls ( Fig. 5K ). These data indicate that the epidermal hyperplasia in Pten mutant skin is composed of both proliferative and differentiated keratinocytes and is not caused by a failure to initiate terminal differentiation. ; MMTV-cre animals, seeded at low density, and grown in culture for several days. Pten mutant keratinocytes grew more rapidly than control cells (Fig. 3A) . The majority of control keratinocytes have exhausted their proliferative potential and die by 21 days. However, many foci of Pten-null keratinocytes remained attached to the culture dish by this time point (Fig. 3B) , indicating that the enhanced growth seen in Pten mutant keratinocytes is associated with a significant expansion of these cells over time. We investigated the proportion of proliferating and dead cells but were not able to detect a statistically significant difference in proliferation or viability in the presence or absence of Pten (data not shown). Therefore, we cannot determine the relative contributions of either proliferation or death to the enhanced growth of Pten-deficient cultured keratinocytes, and it is possible that effects on both of these phenomena contribute to this phenotype.
The ability of Pten to regulate keratinocyte proliferation in vivo was investigated by immunohistochemistry for proliferation marker Ki67 in the epidermis of Pten mutant and control animals. Coimmunohistochemistry for K14 and Ki67 demonstrate that proliferation is restricted to the basal layer in both control and Pten mutant mice ( Fig. 5 I and J) . However, basal keratinocytes of the Pten mutant epidermis had a near 2-fold increase in proliferation compared with control cells at 3 wk (Fig. 3G) .
Complete Penetrance and Early Onset of High-Grade Neoplasia in Pten
Mutant Prostate. To investigate the consequences of Pten loss in the prostate, developing and mature tissue was collected from Pten mutant males and histologically analyzed. Whereas development of the murine prostate gland begins late in embryogenesis, the majority of ductal morphogenesis in this organ occurs within the first 2 postnatal weeks (22, 23) . Prostatic epithelium from six of nine Pten loxP/loxP ; MMTV-cre animals was hyperplastic by 5 days of age compared with controls (Fig. 4D) . By 2 wk, high-grade prostate intraepithelial neoplasia (HGPIN) and prostate carcinoma in situ (PCIS) were present in all Pten mutant males (n ϭ 4͞4, Table 1 ). HGPIN lesions were composed of a papillary proliferation of epithelial cells with cellular atypia. In PCIS, epithelial cells formed a solid bridge across the lumen that filled the glandular structure (Fig. 4E) . Features of atypia evident in HGPIN and PCIS as early as 2 wk include hyperchromasia, prominent nucleoli, nuclear enlargement, and loss of polarity. From 3 wk onwards, additional features of atypia, including pleiomorphism and cell enlargement, were observed in these prostate lesions (Fig. 6B, which is published as supporting  information) . Surface area measurements demonstrated that prostate cells lacking Pten were Ͼ50% larger than control cells at 3 wk (Fig. 4L) . Necrosis was frequently observed within the lumen of PCIS lesions (Fig. 6D) , indicative of comedocarcinoma (11) .
Consistent with Pten's ability to negatively regulate PKB͞Akt activity, phospho-PKB expression was elevated in Pten-null prostate compared with control glands in which expression was undetectable (Fig. 4I) . Up-regulation of PKB activity in this organ was detected as early as P5 in Pten loxP/loxP ; MMTV-cre males (data not shown). (Fig. 4K) . Together, these findings demonstrate that prostate epithelium can differentiate in the absence of Pten and that the prostate tumors were luminal in nature. In addition, basal and luminal cells were each increased by Ͼ3-fold in the Pten mutant glands compared with heterozygous controls (Fig. 6E) . The increased cellularity in both the stem cell and differentiated populations of Pten mutant glands suggests that, similarly to the Pten-null epidermis, neoplasia results from expansion of the basal cell population.
Increased Proliferation in Pten-Null Prostate Epithelium. To determine whether increased proliferation contributes to neoplasia in the Pten mutant prostate, immunohistochemistry for Ki67 was performed. Similarly to keratinocytes in Pten mutant skin, the percentage of Ki67-positive epithelial cells was Ͼ2-fold greater in the prostates of Pten loxP/loxP ; MMTV-cre males compared with heterozygous controls (Fig. 3 E-G) . These findings indicate that Pten negatively regulates proliferation of the mouse prostate. ; MMTV-cre mice were sick or dead by 14 wk (Fig. 7 , which is published as supporting information). Internal organs of Pten Total  3͞27  3͞27  2͞27  0͞27  38͞38  27͞38  37͞38  15͞38  %  11  11  7  0  100  71  97  39 Neoplasia includes all lesions showing HGPIN, PCIS, and͞or invasion. *Genotypes of control mice 2 wk of age were Pten wt͞loxP ; MMTV-cre, Pten wt͞loxP , or Pten loxP͞loxP . mutant mice were collected and analyzed for potential abnormalities. Thymic lymphomas were found in the majority of Pten loxP/loxP ; MMTV-cre mice by 14 wk (Table 2 , which is published as supporting information), and it is believed that these malignancies were responsible for the premature mortality of these animals. The development of lymphomas upon loss of Pten in T-lymphocytes by this age is in agreement with previous studies (13, 25) . The early mortality of Pten mutant mice due to the incidence of lymphomas precluded analyses of these mice for progression of malignancies affecting the skin and prostate past 14 wk. Skin, breast, and thyroid tumors were not observed in Pten loxP/loxP ; MMTV-cre mice before they succumbed to lymphomas. In addition, prostate tumors did not metastasize to the internal organs of the Pten mutant males, and bone metastases are highly unlikely, given the focally invasive nature of these tumors by the time these animals died of lymphoid malignancy.
Discussion
Pten heterozygous mice are highly susceptible to tumor development (4, 12) . Loss of heterozygosity for Pten in these tumors implies that homozygous inactivation of Pten is necessary for development of neoplasias. Analysis of mice with tissue-specific deletion of both Pten alleles revealed that homozygous inactivation of Pten results in hyperproliferation and neoplasia in lymphoid tissues, gonads, breast, and neural stem cells (13) (14) (15) (26) (27) (28) . Neoplastic changes in Pten-null lymphocytes, keratinocytes, neural cells, and mammary epithelial cells are also associated with a resistance to apoptotic stimuli. Consequently, a high frequency of tumors arise from Pten-null T lymphocytes, breast, and germ cells. These studies demonstrate a physiological role for Pten in regulation of proliferation and apoptosis. However, Pten nullizygosity does not result in neoplastic proliferation of all cell types. Deletion of Pten in terminally differentiated brain and heart cells causes enlargement of these organs as a consequence of increased cell size (28, 29) . Thus, consistent with earlier studies in Drosophila, Pten functions as an important regulator of cell and organ size (28) .
In the current study, we report that inactivation of Pten in mouse skin and prostate results in neoplasia. Overgrowth of these organs was the result of increased proliferation and, in the prostate, increased cell size. Potential defects in apoptosis are unlikely to contribute to the phenotypes described in Pten mutant skin and prostate because basal rates of apoptosis are negligible in these tissues at the tested times (30, 31) . Significantly, the prostate and skin lesions in Pten loxP/loxP ; MMTV-cre mice have early onset and are completely penetrant, indicating that loss of Pten is sufficient for neoplastic proliferation of these tissues.
Development and growth of the epidermis and prostate are controlled by components of PI3K signaling. Overexpression of transforming growth factor ␣ (TGF-␣) or insulin-like growth factor 1 (IGF-1) in mouse keratinocytes results in wrinkled skin and epidermal hyperplasia as well as coat abnormalities comparable to those of Pten mutant mice (32, 33) . Significantly, these transgenic mice develop benign skin tumors with age. In contrast, mice lacking EGF receptor, IGF-1 receptor, Fgfr2-IIIB, or both Akt1 and Akt2 have a thin epidermis because of a reduction in proliferation (34) (35) (36) . In the prostate, overexpression experiments have implicated Igf-1, TGF-␣, Fgf8b, and PKB͞Akt in development and tumorigenesis of this gland (1, 37, 38) . Further, growth of Igf-1-null prostate epithelium is impaired (37) . Given Pten's ability to antagonize growth factor-mediated PI3K signaling, up-regulation of PI3K-PKB͞Akt signaling likely contributes to neoplasias in Pten mutant skin and prostate. Consistent with this notion, increased PKB phosphorylation was observed in both Pten-null keratinocytes and prostate.
Whereas PTEN mutations are rare in human basal and squamous cell carcinomas, loss of PTEN activity and upregulation of PI3K signaling occurs during mouse skin carcinogenesis (21, 39) . Cutaneous tumors were not observed in Pten loxP/ loxP; MMTV-cre mice by the time they died of thymic lymphomas at 3 months of age. The absence of skin tumors in young Pten mutant mice is in agreement with a recent study in which Pten was deleted specifically in keratinocytes by the use of the keratin 5 promoter-driven Cre (40) . These mice developed squamous papillomas and squamous cell carcinomas only by 4-8 months of age.
The breast, endometrial, and thyroid tumors that arise in Pten heterozygous mice overlap with malignancies of certain CD patients (7, 11, 12) . Hamartomas characteristic of CD are present in some organs of Pten heterozygous mice such as the intestine, but not in the skin or brain (11, 12) . We and others previously reported that loss of both Pten alleles is sufficient for development of a mouse phenocopy of Lhermitte-Duclos disease, a rare neural manifestation of CD characterized by macrocephaly and hypertrophied cerebellar neurons (16, 41) . Hamartomas originating from mucocutaneous tissues are found in Ͼ90% of CD patients, and there is limited evidence that PTEN loss of heterozygosity occurs in these growths (7, 42) . It is therefore possible that loss of the wild-type PTEN allele is sufficient for development of these growths. Indeed, benign keratoses similar to those that develop on the hands and feet of CD patients were found on the paws and feet of Pten loxP/loxP ; MMTV-cre mice (20, 21) . Whereas benign tumors were not found in other mucocutaneous tissues of Pten mutant mice such as the hair follicle and oral cavity, hyperplasia was detected at these sites. These findings indicate that, in mice, loss of Pten is sufficient for hyperproliferation of mucocutaneous tissues affected in CD patients. Together, these data imply that loss of both PTEN alleles is involved in mucocutaneous hamartoma formation in humans with CD and suggest that Pten loxP/loxP ; MMTV-cre mice may offer valuable insight into this manifestation of CD. Interestingly, the spectrum of tissues predisposed to tumor development in CD patients does not include the thymus or prostate as is seen in the Pten loxP/loxP ; MMTV-cre mice. However, PTEN mutations have been described in sporadic human prostate tumors (3) .
Despite the high rate of loss of heterozygosity on various chromosomes in prostate cancer, few loss-of-function animal models of this disease exist. Mice deficient in homeobox gene Nkx3.1 or retinoid receptor RXR␣ develop HGPINs by 1 year of age (37) . The long latency period for tumor development implies that additional genetic mutations are required for neoplasia to occur in the prostate in these models. The high frequency of chromosome 10 deletions and PTEN mutations in human prostate cancers suggests that inactivation of this tumor suppressor is an important step during prostate tumorigenesis. In mice, Pten haploinsufficiency accelerates tumorigenesis in various prostate cancer-prone backgrounds (43) (44) (45) . The age of onset of prostate neoplasias in Nkx3.1 Ϫ/Ϫ , p27
, and transgenic adenocarcinoma of mouse prostate (TRAMP) mice is reduced in a Pten heterozygous background. However, prostate lesions still take several months to develop in these compound mutants.
In this study, we report that inactivation of Pten alone results in high-grade prostate neoplasia within only 2 wk of age. Prostate tissue from Pten loxP/loxP ; MMTV-cre neonates is hyperplastic and progresses to carcinoma in situ before development of this gland is complete (23) , and these lesions frequently become invasive. The only other existing animal model with a prostate phenotype comparable to that of the Pten mutant mice is the TRAMP transgenic mice, which rely on dysregulation of multiple signaling molecules (37) . In contrast to the TRAMP mice, the secretory nature of prostate tumors in the Pten mutant animals resembles that of human prostate adenocarcinomas (24) .
Importantly, the early onset and complete penetrance of prostate lesions in the Pten loxP/loxP ; MMTV-cre mice indicate that inactivation of Pten alone is sufficient for the initiation of (46) , and these Pten mutant animals develop metastatic prostate lesions with age. Prostatespecific Pten conditional mutants of this nature will also be applicable for therapy and prevention trials. Together, analyses of the various conditional Pten-knockout mice indicate that this gene is a critical regulator of proliferation in the mouse prostate and that maintenance of Pten signaling is of paramount importance to prevent initiation and progression of prostate tumorigenesis.
The phenotypes described in the Pten loxP/loxP ; MMTV-cre mice demonstrate an important role for Pten in tissue homeostasis of the skin and prostate. Further study of conditional Pten mutant animals will help to advance our understanding of Pten signaling, growth control, and tumorigenesis in these organs.
